Clarity

Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

Retrieved on: 
Monday, March 4, 2024

The presentations include new data for its oral small molecule inhibitor of tau aggregation (BIIB113), as well as presentations providing insights into the underlying mechanisms of Alzheimer’s disease.

Key Points: 
  • The presentations include new data for its oral small molecule inhibitor of tau aggregation (BIIB113), as well as presentations providing insights into the underlying mechanisms of Alzheimer’s disease.
  • In addition to BIIB113, Biogen is researching the potential of tau reduction in AD with its investigational antisense oligonucleotide targeting the microtubule associated protein tau (MAPT) gene (BIIB080).
  • Oral presentation: Results of the first in-human, randomized, blinded, placebo-controlled, single- and multiple-ascending dose study of BIIB113 in healthy volunteers.
  • Oral presentation: Lecanemab for the treatment of early Alzheimer’s disease; the extension of efficacy results from Clarity AD.

BioArctic: Latest data on lecanemab to be presented at the 2024 AD/PD™ congress

Retrieved on: 
Thursday, February 29, 2024

In total, lecanemab will be featured in six presentations, including an oral presentation by BioArctic's founder Professor Lars Lannfelt.

Key Points: 
  • In total, lecanemab will be featured in six presentations, including an oral presentation by BioArctic's founder Professor Lars Lannfelt.
  • At AD/PD, BioArctic will present one oral presentation and one poster on lecanemab, both focused on the binding properties of lecanemab to various types of Aβ of lecanemab compared to several other Aβ antibodies.
  • In addition, the differences in the binding properties of multiple anti-amyloid (Aβ) antibodies to various types of Aβ and other data will be presented.
  • Lecanemab for the treatment of early Alzheimer's disease: the extension of efficacy results from Clarity AD

BioArctic: Latest data on lecanemab to be presented at the 2024 AD/PD™ congress

Retrieved on: 
Thursday, February 29, 2024

In total, lecanemab will be featured in six presentations, including an oral presentation by BioArctic's founder Professor Lars Lannfelt.

Key Points: 
  • In total, lecanemab will be featured in six presentations, including an oral presentation by BioArctic's founder Professor Lars Lannfelt.
  • At AD/PD, BioArctic will present one oral presentation and one poster on lecanemab, both focused on the binding properties of lecanemab to various types of Aβ of lecanemab compared to several other Aβ antibodies.
  • In addition, the differences in the binding properties of multiple anti-amyloid (Aβ) antibodies to various types of Aβ and other data will be presented.
  • Lecanemab for the treatment of early Alzheimer's disease: the extension of efficacy results from Clarity AD

Revyrie acquires Myntr to expand upon the venture studio's e-commerce capabilities

Retrieved on: 
Wednesday, January 17, 2024

Revyrie acquires Myntr in all cash deal, expanding e-commerce capabilities and strengthening digital portfolio.

Key Points: 
  • Revyrie acquires Myntr in all cash deal, expanding e-commerce capabilities and strengthening digital portfolio.
  • This acquisition bolsters Revyrie's Digital Commerce portfolio and expands its delivery footprint as a leading provider of retail services and solutions.
  • Founded by Dan Faiman, Revyrie leverages its global resources to help launch and incubate cutting edge brands and technologies.
  • "We are thrilled to welcome Myntr along with their valued customers and partners to Revyrie.

Eisai: "LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in China

Retrieved on: 
Wednesday, January 10, 2024

Preparations for launch within the second quarter of Eisai's FY 2024 (July 1 - September 30, 2024) are underway.

Key Points: 
  • Preparations for launch within the second quarter of Eisai's FY 2024 (July 1 - September 30, 2024) are underway.
  • LEQEMBI is the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism.
  • China is the third country to grant marketing approval, following the traditional approval in the U.S. in July 2023 and Japanese approval in September 2023.
  • ** An online business of Jingyi Weixiang (Shanghai) Health Industry Development Limited Company, a joint venture company with JD Health.

Leqembi® approved for the treatment of Alzheimer's disease in China

Retrieved on: 
Tuesday, January 9, 2024

China is the third country to grant marketing approval, following the traditional approval in the United States in July 2023 and Japanese approval in September 2023.

Key Points: 
  • China is the third country to grant marketing approval, following the traditional approval in the United States in July 2023 and Japanese approval in September 2023.
  • Leqembi is the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism.
  • Eisai will distribute the product in China and will conduct information provision activities through specialized Medical Representatives.
  • Dosage and administration: The usual dose of lecanemab (recombinant) is 10mg/kg infused intravenously over approximately 1 hour, once every 2 weeks.

Leqembi® approved for the treatment of Alzheimer's disease in China

Retrieved on: 
Tuesday, January 9, 2024

China is the third country to grant marketing approval, following the traditional approval in the United States in July 2023 and Japanese approval in September 2023.

Key Points: 
  • China is the third country to grant marketing approval, following the traditional approval in the United States in July 2023 and Japanese approval in September 2023.
  • Leqembi is the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism.
  • Eisai will distribute the product in China and will conduct information provision activities through specialized Medical Representatives.
  • Dosage and administration: The usual dose of lecanemab (recombinant) is 10mg/kg infused intravenously over approximately 1 hour, once every 2 weeks.

Clarity Child Guidance Center Breaks Ground on Vital Renovations to Increase Capacity for Children facing Mental Health Challenges

Retrieved on: 
Friday, December 29, 2023

SAN ANTONIO, Dec. 29, 2023 /PRNewswire-PRWeb/ -- Clarity Child Guidance Center broke ground during a special ceremony on Wednesday, September 20, 2023, on renovations being made possible through its "HEROES: The Campaign for Clarity." When complete, this $16 million capital campaign will allow Clarity to serve an additional 1,000 kids a year—bringing the annual total to an annual average of 9,000 children and teens--ensuring that every child and family who needs behavioral health services can receive them. Currently, about 60% of children treated at Clarity are uninsured, underinsured or low-income. San Antonio-based Clarity Child Guidance Center--the only nonprofit in South Texas providing a continuum of mental health care for children ages 3-17 and their families to manage conditions ranging from ADHD and anxiety to suicidal ideation, bipolar disorder and/or schizophrenia—is indeed experiencing a 27% increase in inpatient hospitalizations, 19% increase in children who were suicidal, a 65% increase in inpatient treatment of kids that have never been seen in the mental health system before, and a 159% increase in the crisis services department. (More on Clarity below.)

Key Points: 
  • SAN ANTONIO, Dec. 29, 2023 /PRNewswire-PRWeb/ -- Clarity Child Guidance Center broke ground during a special ceremony on Wednesday, September 20, 2023, on renovations being made possible through its "HEROES: The Campaign for Clarity."
  • Currently, about 60% of children treated at Clarity are uninsured, underinsured or low-income.
  • "School violence, isolation of the pandemic, and return to the classroom for the increase in demand.
  • Bexar County Judge Peter Sakai and District 8 Councilman Manny Pelaez publicly reaffirmed their commitment to youth mental health for San Antonio area.

SHERO Life & Empowerment Coaching Launches The Empowerment Blueprint

Retrieved on: 
Tuesday, December 26, 2023

Jasper, Georgia--(Newsfile Corp. - December 26, 2023) - SHERO Life & Empowerment Coaching launches the Empowerment Blueprint.

Key Points: 
  • Jasper, Georgia--(Newsfile Corp. - December 26, 2023) - SHERO Life & Empowerment Coaching launches the Empowerment Blueprint.
  • The Empowerment Blueprint is designed for women ready to embrace transformative change and emerge empowered to live on their terms.
  • "The Empowerment Blueprint is designed to help women rewrite their narratives, step into their authentic selves, and take control of their lives," says Jennifer Perri.
  • The key benefits of The Empowerment Blueprint include:
    ● Personal Transformation: Assisting participants in reimagining their life narratives and embracing their authentic identities.

Creative Realities and Black Rifle Coffee Join Forces to Revolutionize the Customer Experience

Retrieved on: 
Wednesday, December 13, 2023

Inspired by the support of Back Rifle Coffee enthusiasts, the coffee chain launched a branded retail offering to create a deeper sense of community and provide a unique experience for coffee lovers.

Key Points: 
  • Inspired by the support of Back Rifle Coffee enthusiasts, the coffee chain launched a branded retail offering to create a deeper sense of community and provide a unique experience for coffee lovers.
  • To achieve these goals, Black Rifle Coffee embraced Creative Realities' purpose-built Clarity CMS, a solution designed to streamline and elevate the digital experience.
  • “At Black Rifle Coffee, we take pride in our commitment to providing exceptional experiences for our customers and team members, many of whom have served in our nation’s military,” said Tom Davin, Black Rifle Coffee Co-CEO.
  • “At Creative Realities, we believe in pushing the boundaries of what's possible in customer engagement,” said Rick Mills, CEO of Creative Realities.